Rigel’s VEPPANU Launch Signals Expanded Growth Amid Q2 Profitability

Rigel Pharmaceuticals outlined a broadened growth strategy at the H.C. Wainwright conference in September 2026, highlighting VEPPANU’s commercial launch as a pivotal milestone in its expansion beyond a single-product business. The company reported Q2 2024 net product sales of $67 million, a 14% year-over-year increase, alongside profitability for eight consecutive quarters, with after-tax net income of $17.3 million. Its cash position stood at $95 million at the end of Q2, following a $70 million upfront payment for VEPPANU’s acquisition in mid-June, which became commercially available on August 13—a 60-day timeline from deal closure to launch. Full-year revenue guidance ranged from $285 million to $295 million, with net product sales (excluding VEPPANU) projected between $255 million and $265 million, and contract revenues of $30 million. The acquisition included $320 million in potential milestone payments, including $60 million for regulatory milestones and $260 million for commercial milestones, alongside royalties in the mid-teens to mid-20s percentage range, and up to $40 million in additional funding over four years for clinical studies. Rigel’s Chief Financial Officer, Dean Schorno, emphasized the transaction’s role in transforming the company from a one-product entity to a portfolio with three approved drugs, a growing pipeline, and a stable financial foundation. VEPPANU, approved for ER-positive, HER2-negative, estrogen receptor-mutated advanced or metastatic breast cancer, marked Rigel’s first PROTAC therapy, demonstrating a 2.4-fold improvement in median progression-free survival (PFS) in the VERITAC-2 Phase III trial, from 2.1 months to 5 months. The drug’s market opportunity is substantial, targeting approximately 170,000 U.S. metastatic breast cancer patients, with about 20,000 eligible in second- and third-line settings, and a potential addressable market exceeding $1 billion. Rigel’s pipeline also includes R289, an IRAK1/4 inhibitor in Phase I-B for relapse-refractory lower-risk myelodysplastic syndromes (MDS), with Fast Track and Orphan Drug designations. Early data showed 33% of transfusion-dependent patients achieving independence, with a median duration of response exceeding 22.9 months. The company’s commercial strategy includes deploying 40 field sales representatives to community oncologists and 10 to academic centers, reflecting a focus on expanding access to its therapies. Schorno underscored VEPPANU’s potential as a transformative growth driver, positioning Rigel for sustained expansion into the 2030s.